Answers are grounded in this paper and cite their sources.
Consensus pathway aims to reduce cardiovascular complications in patients with type 2 diabetes, suggesting better care strategies.
Type 2 diabetes is a major threat to human health in the 21st century. More than half a billion people may suffer from this pandemic disease in 2030, leading to a huge burden of cardiovascular complications. Recently, 2 novel antidiabetic agents, glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, reduced cardiovascular complications in a number of randomized control trials. To integrate new information and to achieve a streamlined process for better patient care, a working group was appointed by the Taiwan Society of Cardiology to formulate a stepwise consensus pathway for these therapies to reduce cardiovascular events in patients with type 2 diabetes. This consensus pathway is complementary to clinical guidelines, acting as a reference to improve patient care.
No takes yet. Share an insight, caveat, or question.
Chiang et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: